Who’s Your Inventor?: Contradictory Declarations Leads to Summary Judgment Reversal
Supreme Court to Reexamine the Interplay Between Patents and Unlawful Tying Agreements
Will US Courts Adjudicate Foreign Patents or Will Comity Prevail?
“Optional” disclosure in prior art reference overcomes negative claim limitation.
On Remand: Knorr-Bremse District Court Finds Willfulness Even Without Adverse Inference Rule
“Means-plus-function” Claim Indefinite For Lack Of Corresponding Structure
CAFC: Patent Laws Preempt Unjust Enrichment Claim
SmithKline Beecham v. Apotex: A Conclusion?
Branding-Energy of the Volkswagen Beetle
Seed License Agreement Does Not Implicate Plant Variety Protection Act
PTO Board: Disclosure of Sequence Enables at least 5% of Natural Variance.
Ex parte Bandman, No. 2004-2319, (BPAI 2005)
By Donald Zuhn
In an appeal from a final rejection, the PTO Board reversed rejections based on both the written description and enablement requirements of 35 U.S.C. § 112, first paragraph, and entered a new ground of rejection under 35 U.S.C. § 112, second paragraph one of the claims. (U.S. Application No. 09/915,694).
Pointedly, the Board found that claims directed to a naturally occurring amino acid (or polynucleotide) sequence at least 95% identical to the disclosed amino acid (or polynucleotide) sequence were enabled and met the written description requirement.